Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by UK REACH Regulation SI 2019/758

SAFETY DATA SHEET



MM 9153 WaterBase 900+ Series Translucent Maroon

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier	
Product name	: MM 9153 WaterBase 900+ Series Translucent Maroon
Product code	: 99153
Product description	: Not available.
Product type	: Liquid.

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses	
Professional spray painting, near-industrial setting Use in coatings - Basecoat	

Uses advised against Not applicable.

1.3 Details of the supplier of the safety data sheet

Valspar b.v. Zuiveringweg 89 8243 PE Lelystad The Netherlands tel: +31 (0)320 292200

e-mail address of person : msds@valspar.com responsible for this SDS

National contact

Sherwin-Williams UK Limited Avenue One Station Lane, Witney, United Kingdom Oxfordshire OX28 4XR

1.4 Emergency telephone number

National advisory body/Poison Centre		
Telephone number	: UK: 0-800-014-8126	

CALL: +(44)-870-8200418 (Hours of operation - 24 hours)

<u>Supplier</u>

Telephone number : Call: +31 (0)320 292200 (8:30AM - 5PM)

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture Product definition : Mixture

Classification according to UK CLP/GHS Skin Sens. 1, H317

The product is classified as hazardous according to UK CLP Regulation SI 2019/720 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Hazard pictograms



Signal word

Date of issue/Date of revision

: 10/25/2023

SECTION 2: Hazards identification

Hazard statements	1	May cause an allergic skin reaction.
Precautionary statements		
Prevention	1	Wear protective gloves. Avoid breathing vapour or spray.
Response	:	Take off contaminated clothing and wash it before reuse. IF ON SKIN: Wash with plenty of water. If skin irritation or rash occurs: Get medical advice or attention.
Storage	1	Not applicable.
Disposal	:	Dispose of contents and container in accordance with all local, regional, national and international regulations.
Supplemental label elements	:	Not applicable.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:	Not applicable.
Special packaging requirem	en	t <u>s</u>
Containers to be fitted with child-resistant fastenings	:	Not applicable.
Tactile warning of danger	:	Not applicable.
2.3 Other hazards		
Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII	:	This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
Other hazards which do not result in classification	:	None known.

SECTION 3: Composition/information on ingredients

Product/ingredient name	Identifiers	%	Classification	Туре
2-butoxyethanol	REACH #: 01-2119475108-36 EC: 203-905-0 CAS: 111-76-2 Index: 603-014-00-0	<10	Acute Tox. 4, H302 Acute Tox. 3, H331 Skin Irrit. 2, H315 Eye Irrit. 2, H319	[1] [2]
2,9-dimethylanthra[2,1,9-def: 6,5,10-d'e'f']diisoquinoline-1,3,8,10 (2H,9H)-tetrone	REACH #: 01-2119972292-35 EC: 226-866-1 CAS: 5521-31-3	≤3	STOT RE 2, H373 (inhalation)	[1]
2,4,7,9-tetramethyldec-5-yne- 4,7-diol	REACH #: 01-2119954390-39 EC: 204-809-1 CAS: 126-86-3	≤0.3	Eye Dam. 1, H318 Skin Sens. 1B, H317 Aquatic Chronic 3, H412	[1]
(2-methoxymethylethoxy)propanol	REACH #: 01-2119450011-60 EC: 252-104-2 CAS: 34590-94-8	≤0.3	Not classified.	[2]
3(2H)-Isothiazolone, 2-methyl-	REACH #: 01-2120764690-50 EC: 220-239-6 CAS: 2682-20-4	<0.01	Acute Tox. 3, H301 Acute Tox. 3, H311 Acute Tox. 2, H330 Skin Corr. 1B, H314 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 (M=10) Aquatic Chronic 1,	[1]

MM 9153 WaterBase 900+ Series Translucent Maroon

SECTION 3: Composition/information on ingredients

H410 (M=1) EUH071
See Section 16 for the full text of the H statements declared above.

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

<u>Type</u>

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

Occupational exposure limits, if available, are listed in Section 8.

CTION 4. Eirot aid maaauraa S

SECTION 4: First al	u measures
4.1 Description of first aid n	neasures
Eye contact	: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention if irritation occurs.
Inhalation	: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention if adverse health effects persist or are severe. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
Skin contact	: Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.
Ingestion	: Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Protection of first-aiders	: No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.
4.2 Most important symptor	ns and effects, both acute and delayed
Over-exposure signs/symp	<u>otoms</u>
Eye contact	: No specific data.

Inhalation : No specific data. Skin contact : Adverse symptoms may include the following: irritation redness Ingestion : No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician : In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

Date of issue/Date of revision : 10/25/2023	Date of previous issue	: 2/7/2023	Version	:1	3/17
---	------------------------	------------	---------	----	------

SECTION 4: First aid measures

Specific treatments : No specific treatment.

SECTION 5: Firefighting measures

	-
5.1 Extinguishing media	
Suitable extinguishing media	: Use an extinguishing agent suitable for the surrounding fire.
Unsuitable extinguishing media	: None known.
5.2 Special hazards arising f	rom the substance or mixture
Hazards from the substance or mixture	: In a fire or if heated, a pressure increase will occur and the container may burst.
Hazardous combustion products	: Decomposition products may include the following materials: carbon dioxide carbon monoxide nitrogen oxides
5.3 Advice for firefighters	
Special protective actions for fire-fighters	: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
Special protective equipment for fire-fighters	: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

		····· · · · · · · · · · · · · · · · ·
For non-emergency personnel	:	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
For emergency responders	:	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
6.2 Environmental precautions	:	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
6.3 Methods and material for o	coi	ntainment and cleaning up
Small spill	:	Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Large spill	:	Stop leak if without risk. Move containers from spill area. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations (see Section 13). Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spill product. Note: see Section 1 for emergency contact information and Section 13 for waste disposal.
6.4 Reference to other sections	:	See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

Date of issue/Date of revision : 10/25/2023 Date	e of previous issue : 2/7/2023	Version : 1 4/17
--	--------------------------------	------------------

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing vapour or mist. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

7.3 Specific end use(s)

Recommendations	: Not available.
Industrial sector specific	: Not available.
solutions	

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational exposure limits

Product/ingredient name	Exposure limit values			
2-butoxyethanol	EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed			
-	through skin.			
	STEL: 50 ppm 15 minutes.			
	TWA: 25 ppm 8 hours.			
	STEL: 246 mg/m ³ 15 minutes.			
	TWA: 123 mg/m ³ 8 hours.			
(2-methoxymethylethoxy)propanol	EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed			
	through skin.			
	TWA: 308 mg/m ³ 8 hours.			
	TWA: 50 ppm 8 hours.			

Recommended monitoring procedures : Reference should be made to appropriate monitoring standards. Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

DNELs/DMELs

Product/ingredient name	Туре	Exposure	Value	Population	Effects
2-butoxyethanol	DNEL	Long term Oral	6.3 mg/kg bw/day	General population	Systemic
	DNEL	Short term Oral	26.7 mg/ kg bw/day	General population	Systemic
	DNEL	Long term Inhalation	59 mg/m ³	General population	Systemic
	DNEL	Long term Inhalation	98 mg/m³	Workers	Systemic
	DNEL	Short term Inhalation	147 mg/m³	General population	Local
	DNEL	Short term Inhalation	246 mg/m³	Workers	Local
e of issue/Date of revision : 10	/25/2023	Date of previous issue	: 2/7/202	3	Version : 1 5/

SECTION 8: Exposure controls/personal protection

2.9-dimethylanthra[2,1,9-def: 6,510-d*f]discoulnoline-1.3,8,10 DNEL DNEL Short term inhalation DNEL (21,94)-Letrone Short term inhalation DNEL DORL (21,94)-Letrone Short term inhalation DNEL DORL DORL (21,94)-Letrone Short term inhalation DNEL DORL DORL DORL DORL DORL DORL DORL DOR	SECTION 8: Exposure cont	rols/p	ersonal prote	ction		
2.9-dimethylanthra[2,1,9-def: 6.5,10.d*f*[discquinoline-1.3,8,10] ONEL Cong term inhalation 1091 mg/ 125 mg/m² population Workers Systemic 0.11,191-jetrone DNEL Cong term inhalation 1.25 mg/m² Workers Systemic 0.12,191-jetrone DNEL Cong term inhalation 1.25 mg/m² Workers Systemic 0.14,191-jetrone DNEL Cong term Inhalation 1.25 mg/m² Workers Systemic 0.14,191-jetrone DNEL Cong term Dermal 3.3 mg/ Ng bw/day Workers Systemic 0.14,17,9-tetramethyldec-5-yne-4,7-dio DNEL Cong term Dermal Long term Dermal Systemic Systemic 0.14,17,9-tetramethyldec-5-yne-4,7-dio DNEL Cong term Dermal Cong term DNEL Long term Dermal Systemic Systemic 0.14,17,9-tetramethyldec-5-yne-4,7-dio DNEL Long term Dermal Systemic Systemic Systemic 0.14,17,9-tetramethyldec-5-yne-4,7-dio DNEL Long term Dermal Systemic Systemic Systemic 0.14,17,9-tetramethylethoxylpropanol DNEL Short term Dermal Systemic Systemic 0.14,17,9,19 Short term Dari		DNEL	Short term	426 mg/m ³	General	Svstemic
2.9-dimethylanthra[2,1,9-def: 6,5,10-d*f]tiosocumoline-1,3,8,10 DNEL (DNEL 6,5,10-d*f]tiosocumoline-1,3,8,10 Short term inhalation 100 gterm inhalation 1.25 mg/m² Workers Local 2.4,7,9-tetramethyldec-5-yne-4,7-dial NEL DNEL Long term Short term inhalation 1.25 mg/m² Workers Systemic 2.4,7,9-tetramethyldec-5-yne-4,7-dial DNEL DNEL Long term Long term Oral 1.25 mg/m² Workers Systemic 2.4,7,9-tetramethyldec-5-yne-4,7-dial DNEL DNEL Long term Long term Oral 1.67 mg/g General population Systemic 0.43 mg/m² DNEL Long term Long term Oral 0.43 mg/m² General population Systemic 0.44 mg/m² DNEL Long term Long term Oral 0.5 mg/k² General population Systemic 0.43 mg/m² DNEL Long term Long term Oral 0.5 mg/k² General population Systemic 0.44 mg/m² Nortern DNEL Long term Long term 1.5 mg/k² General population Systemic 0.41 mg/m² Nortern DNEL Long term Soft term 1.5 mg/k² General population Systemic 0.42 mg/k² Nortern 1.5 mg/k² General population Systemic Systemic 0.42 mg/k² Long term 1.7 mg/m² General population						-,
2.9-dimethylanthrai2.1.9-def: Inhalation m³ o 1.25 mg/m³ Workers Local 6.5.10-d*f1/discouncine-1.3.8.10 IONEL Long term 1.25 mg/m³ Workers Systemic Inhalation IDNEL Short term 1.25 mg/m³ Workers Systemic Inhalation IDNEL Long term 1.25 mg/m³ Workers Systemic Inhalation IDNEL Long term 1.25 mg/m³ Workers Systemic IDNEL Long term Demail 33.8 mg/ Workers Systemic IDNEL Long term Demail 16.7 mg/ General Systemic IDNEL Long term Demail 16.7 mg/ General Systemic IDNEL Long term Demail 0.5 mg/kg Workers Systemic IDNEL Long term Demail 0.5 mg/kg Workers Systemic IDNEL Long term Demail 0.5 mg/kg Workers Systemic IDNEL Short term Demail 0.5 mg/kg Workers Systemic IDNEL Short term Demail 1.5 mg/kg Workers Systemic IDNEL		DNEL		1091 ma/		Systemic
2.4-methylanthraj2.1.9.def: 6.5.10-def fullsoquinoline-1.3.8.10 DNEL (2H,9H)-tetrone Local Local 2.4.1,9H)-tetrone DNEL (2H,9H)-tetrone Nort term Inhalation DNEL Long term 0ral 1.25 mg/m ³ (25 mg/m ³) Workers Systemic 2.4.7,9-tetramethyldec-5-yne-4.7-diol DNEL DNEL Long term 0ral 10 mg/m ³ (2 mg/m ³) Workers Systemic 2.4.7,9-tetramethyldec-5-yne-4.7-diol DNEL DNEL Long term 0ral 10 mg/m ³ (2 mg/m ³) Workers Systemic DNEL Long term 0ral 0.5 mg/m ³ (2 mg/m ³) General Systemic Systemic DNEL Long term 0ral 0.5 mg/m ³ (2 mg/m ³) General Systemic Systemic DNEL Long term 0ral 0.5 mg/m ³ (2 mg/m ³) General Systemic Systemic DNEL Long term 0ral 0.5 mg/m ³ (2 mg/m ³) General Systemic Systemic DNEL Short term 0ral 0.5 mg/m ³ (2 mg/m ³) General Systemic Systemic DNEL Short term 0ral 1.5 mg/m ³ (2 mg/m ³) Systemic General Systemic Systemic DNEL Short term 0ral 1.5 mg/m ³ (2 mg/m ³) General Systemic Systemic DNEL Long term 0ral 36 mg/m ³ Sort term 0ral Systemic Systemic DNEL Long term 0ral		5.122				ejetenne
6.5.10-d*f*[disequinotime-1.3.8.10] Inhalation 1.25 mg/m Workers Systemic 1.25 mg/m Workers Systemic Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation Input Inhalation Inhalation Inhalation Inhalation In	2 9-dimethylanthra[2 1 9-def	DNEI			Workers	Local
(2H,9H)-tetrone DNEL Short term inhalation DNEL Long term inhalation DNEL 1.25 mg/m ² Workers Workers Systemic 2,4,7,9-tetramethyldec-5-yme-4,7-diol DNEL Long term Dermal DNEL 33.3 mg/ Vorkers Workers Systemic DNEL Long term Oral 0,8 mg/kg General Opulation Systemic DNEL Long term Oral 0,25 mg/kg General Systemic DNEL Long term Oral 0,25 mg/kg General Systemic DNEL Long term Oral 0,33 mg/m General Systemic DNEL Long term Oral 0,43 mg/m General Systemic DNEL Short term Dermal 1,5 mg/kg General Systemic DNEL Short term Dermal 1,5 mg/kg General Systemic DNEL Short term Dermal 1,5 mg/kg General Systemic DNEL Long term Oral 5 mg/kg General Systemic DNEL Long term Oral 5 mg/kg General </td <td></td> <td>DINEL</td> <td></td> <td>1.20 mg/m</td> <td>Wontero</td> <td>Loodi</td>		DINEL		1.20 mg/m	Wontero	Loodi
DNEL inhalationShort term inhalation1.25 mg/m² WorkersWorkersSystemic systemic2,4,7,9-tetramethyldec-5-yne-4,7-diolDNEL DNELLong term Dermal to mg/kg3.3 mg/ kg bw/dayWorkersSystemic population2,4,7,9-tetramethyldec-5-yne-4,7-diolDNEL DNELLong term Oral DNEL16 7 mg/ kg bw/dayGeneral populationSystemic population2,4,7,9-tetramethyldec-5-yne-4,7-diolDNEL DNELLong term Oral DNEL0.25 mg/ to gb w/dayGeneral populationSystemic population2,4,7,9-tetramethyldec-5-yne-4,7-diolDNEL Long term Dermal Inhalation0.45 mg/kg DNELGeneral DorecSystemic populationDNEL DNELLong term Dermal Inhalation0.5 mg/kg DNELGeneral DorecSystemic populationDNEL DNEL DNELShort term Dermal Inhalation0.5 mg/kg DNELGeneral Systemic DorecSystemic populationDNEL DNEL DNEL DNEL Long term Dermal1.2 mg/kg DNEL Long term Dermal InhalationNorkersSystemic DorecDNEL DNEL Long term Oral36 mg/kg DW/dayGeneral DorecSystemic DorecDNEL Long term Dermal Inhalation1.2 mg/kg DW/dayGeneral DorecSystemic DorecDNEL Long term Oral Inhalation36 mg/kg DW/dayGeneral DorecSystemic Dorulation DORELLong term Dermal Inhalation28 mg/kg DW/dayGeneral DW/daySystemic Dorulation DORELStemic 						
2.4.7.9-tetramethyldec-5-yne-4.7-diol DNEL Long term Dermal and the second sec			Short term	1.25 mg/m^3	Workers	Systemic
PNEL Imatation Inhalation DNELDNEL Long term Dermal Uorg term Dermal biolog DNEL1.25 mg/m WorkersWorkers Systemic Moday General Dystemic Systemic Systemic DNEL2.4.7.9-tetramethyldec-5-yne-4.7-diolDNEL DNELLong term Oral Long term Dermal DNELUorg term Oral Long term Dermal DNELWorkers Biolog District 		DINLL		1.25 mg/m	WUIKEIS	Systemic
2.4.7.9-tetramethyldec-5-yne-4.7-diol DNEL Long term Oral 3.0 mg/kg kg bw/day Workers Systemic 2.4.7.9-tetramethyldec-5-yne-4.7-diol DNEL Long term Oral 0.25 mg/ kg bw/day General Systemic DNEL Long term Oral 0.25 mg/ kg bw/day General Systemic DNEL Long term Oral 0.25 mg/ kg bw/day General Systemic DNEL Long term Oral 0.43 mg/m² General Systemic DNEL Long term Oral 0.43 mg/m² General Systemic DNEL Long term Oral 0.5 mg/kg General Systemic DNEL Long term Oral 0.5 mg/kg General Systemic DNEL Long term Oral 0.5 mg/kg General Systemic DNEL Short term Oral 0.5 mg/kg General Systemic DNEL Short term Dermal 1.5 mg/kg General Systemic DNEL Long term Oral 36 mg/kg General Systemic DNEL Long term Oral 36 mg/kg General Systemic DNEL Long term Oral<				$1.25 m a/m^{3}$	Workoro	Svotomio
2.4,7,9-tetramethyldec-5-yne-4,7-dioi DNEL Long term Darmal 33.3 mg/l kg bw/day Workers Systemic 2.4,7,9-tetramethyldec-5-yne-4,7-dioi DNEL Long term Darmal 10 mg/kg bw/day General population Systemic DNEL Long term Oral D.Ket bw/day Downeral Systemic DNEL Long term Dermal 0.5 mg/kg bw/day General Systemic DNEL Long term Dermal 0.5 mg/kg bw/day General Systemic DNEL Long term Dermal 0.5 mg/kg bw/day General Systemic DNEL Short term Oral 0.5 mg/kg bw/day General Systemic DNEL Short term Darmal 0.5 mg/kg bw/day General Systemic DNEL Short term Darmal 0.5 mg/kg bw/day General Systemic DNEL Short term Darmal 1.5 mg/kg bw/day General Systemic DNEL Long term Darmal 1.5 mg/kg bw/day General Systemic DNEL Long term Darmal 1.6 mg/kg bw/day Systemic Systemic DNEL Long term Darmal 1.6 mg/kg bw/day Systemic Systemic DNEL Long term Darmal 1.76 mg/kg bw/day General Systemic DNEL		DNEL		1.25 mg/m	WUIKEIS	Systemic
2.4,7,9-tetramethyldec-5-yne-4,7-diol DNEL Long term Oral bydkay General Systemic 2.4,7,9-tetramethyldec-5-yne-4,7-diol DNEL Long term Oral 0.25 mg/ General Systemic DNEL Long term Oral 0.25 mg/ General Systemic DNEL Long term Oral 0.25 mg/ General Systemic DNEL Long term Dermal 0.43 mg/m² General Systemic DNEL Long term Dermal 0.43 mg/m² General Systemic DNEL Long term Dermal 0.5 mg/kg General Systemic DNEL Short term Dermal 0.5 mg/kg General Systemic DNEL Short term Dermal 1.5 mg/kg General Systemic DNEL Short term Dermal 1.5 mg/kg General Systemic DNEL Short term Dermal 1.5 mg/mg/m² General Systemic DNEL Short term Dermal 1.6 mg/m² Workers Systemic DNEL Long term Oral 36 mg/kg General Systemic DNEL Long term Dermal 36 mg					\A/aul/aua	Quatamia
2,4,7,9-tetramethyldec-5-yne-4,7-diol DNEL Long term Dermal 10 mg/kg General Systemic DNEL Long term Dermal 0.25 mg/ General Systemic DNEL Long term Dermal 0.25 mg/ General Systemic DNEL Long term Dermal 0.25 mg/ General Systemic DNEL Long term Dermal 0.5 mg/kg General Systemic DNEL Long term Dermal 0.5 mg/kg General Systemic DNEL Long term Dermal 0.5 mg/kg General Systemic DNEL Short term Oral 0.5 mg/kg General Systemic DNEL Short term Oral 0.5 mg/kg General Systemic DNEL Short term Oral 0.5 mg/kg General Systemic DNEL Short term 1.29 mg/m General Systemic DNEL Short term 1.26 mg/m General Systemic DNEL Long term Oral 36 mg/kg General Systemic DNEL Long term Dermal 1.76 mg/m General Systemic		DNEL	Long term Dermai		vvorkers	Systemic
2.4.7.9-tetramethyldec-5-yne-4,7-dio DNEL Long term Dermal bw/day population Systemic DNEL Long term Oral 0.25 mg/ General Systemic DNEL Long term Dermal 0.43 mg/m General Systemic DNEL Long term Dermal 0.43 mg/m General Systemic DNEL Long term Dermal 0.5 mg/g General Systemic DNEL Long term Dermal 0.5 mg/g Workers Systemic DNEL Long term Dermal 0.5 mg/g General Systemic DNEL Long term Dermal 0.5 mg/g General Systemic DNEL Long term Dermal 0.5 mg/g Workers Systemic DNEL Short term Dermal 0.75 mg/ General Systemic DNEL Short term Dermal 1.5 mg/kg Workers Systemic DNEL Long term 1.76 mg/m Workers Systemic DNEL Long term Oral 36 mg/kg General Systemic DNEL Long term Oral 36 mg/kg General Systemic DNEL Long term Oral 36 mg/kg General Systemic DNEL Long term Oral 36 mg/kg <td< td=""><td></td><td></td><td></td><td>•</td><td>0</td><td></td></td<>				•	0	
2,4,7,9-tetramethyldec-5-yne-4,7-diol DNEL Long term Dernal 16,7 mg/ bw/day General Systemic 2,4,7,9-tetramethyldec-5-yne-4,7-diol DNEL Long term Oral 0,25 mg/ kg bw/day General Systemic DNEL Long term Dernal 0,25 mg/ kg bw/day General Systemic DNEL Long term Dernal 0,5 mg/kg Systemic DNEL Long term Dernal 0,5 mg/kg Workers DNEL Systemic Systemic Systemic DNEL Short term Oral 0,75 mg/ General Systemic DNEL Short term Dernal 0,75 mg/ General Systemic DNEL Short term Dernal 0,75 mg/ General Systemic DNEL Short term Dernal 1,5 mg/kg Workers Systemic DNEL Short term Dernal 1,5 mg/kg Workers Systemic DNEL Short term Dernal 1,76 mg/m Workers Systemic DNEL Short term Dernal 1,76 mg/m Workers Systemic DNEL Short term Dernal 1,76 mg/m Workers Systemic DNEL Long term Oral 36 mg/kg General Systemic DNEL Long term Oral <		DNEL	Long term Oral			Systemic
2,4,7,9-tetramethyldec-5-yne-4,7-dio DNEL Long term Oral kg bw/day population Systemic DNEL Long term Dermal 0.25 mg/ General Systemic DNEL Long term Dermal 0.43 mg/m General Systemic DNEL Long term Dermal 0.5 mg/kg Workers Systemic DNEL Long term Dermal 0.5 mg/kg Workers Systemic DNEL Long term Dermal 0.5 mg/kg Workers Systemic DNEL Short term Oral 0.75 mg/ General Systemic DNEL Short term Dermal 0.75 mg/ General Systemic DNEL Short term Dermal 0.75 mg/ General Systemic DNEL Short term Dermal 1.5 mg/kg Workers Systemic DNEL Long term Dermal 1.7 mg/kg Workers Systemic DNEL Long term Oral 36 mg/kg General Systemic DNEL Long term Oral 36 mg/kg General Systemic DNEL Long term Oral 36 mg/kg General Systemic DNEL Long term Dermal 1.1 mg/kg General Systemic DNEL Long term Dermal 36 mg/						
2.4,7,9-tetramethyldec-5-yme-4,7-diol DNEL Long term Oral 0.25 mg/ 0.25 mg/ 0.25 mg/ by bw/day General opoulation Systemic yopulation DNEL Long term Dermal 0.43 mg/m ² bw/day General population Systemic population DNEL Long term Dermal 0.5 mg/ bw/day General population Systemic DNEL Short term Oral 0.5 mg/ bw/day General Systemic DNEL Short term Dermal 0.5 mg/ bw/day General Systemic DNEL Short term Dermal 0.5 mg/ bw/day General Systemic DNEL Short term Dermal 1.5 mg/ bw/day General Systemic DNEL Short term Dermal 1.5 mg/ bw/day Workers Systemic DNEL Long term 1.7 mg/m Workers Systemic DNEL Long term Oral 36 mg/kg General population Systemic DNEL Long term Oral 36 mg/kg General population Systemic DNEL Long term Oral 36 mg/kg General population Systemic DNEL Long term Oral 36 mg/kg General population <td< td=""><td></td><td>DNEL</td><td>Long term Dermal</td><td></td><td></td><td>Systemic</td></td<>		DNEL	Long term Dermal			Systemic
(2-methoxymethylethoxy)propanol DNEL Long term Dermal 0.25 mg/l 0.25 mg/l 0.25 mg/l population Systemic population (2-methoxymethylethoxy)propanol DNEL Long term Dermal 0.5 mg/kg General Systemic DNEL Long term Dermal 0.5 mg/kg General Systemic DNEL Long term Dermal 0.5 mg/kg General Systemic DNEL Short term Oral 0.75 mg/ General Systemic DNEL Short term Dermal 0.75 mg/kg General Systemic DNEL Short term Dermal 1.5 mg/kg Workers Systemic DNEL Short term 1.28 mg/m ³ Workers Systemic DNEL Short term 1.76 mg/m ³ Workers Systemic Inhalation DNEL Long term 1.76 mg/m ³ Workers Systemic Inhalation DNEL Long term Oral 36 mg/kg General Systemic DNEL Long term Oral 36 mg/kg General Systemic DNEL Long term Dermal 1.7 mg/m ³ General Systemic DNEL Long term Oral 36 mg/kg General Systemic DNEL Long term Dermal 12 mg/m ³ General<						
DNEL (2-methoxymethylethoxy)propanolDNEL Long term Inhalation0.25 mg/s kg bw/day 0.75 mg/ 0.75 mg/ 	2,4,7,9-tetramethyldec-5-yne-4,7-diol	DNEL	Long term Oral	•		Systemic
(2-methoxymethylethoxy)propanol DNEL Long term 0.43 mg/m ³ General Systemic DNEL Long term Dermal 0.5 mg/kg Workers Systemic DNEL Short term Oral 0.75 mg/ General Systemic DNEL Short term Oral 0.75 mg/ General Systemic DNEL Short term Dermal 0.75 mg/ General Systemic DNEL Short term Dermal 0.75 mg/ General Systemic DNEL Short term Dermal 1.5 mg/kg Workers Systemic DNEL Short term Dermal 1.76 mg/s General Systemic DNEL Short term Oral 36 mg/kg General Systemic DNEL Long term Oral 36 mg/kg General Systemic DNEL Long term Oral 36 mg/kg General Systemic DNEL Long term Dermal 121 mg/kg General Systemic DNEL Long term Dermal 121 mg/kg General Systemic Johalation DNEL Long term 308 mg/m ³ Workers Systemic Johalation DNEL Long term 308 mg/m ³ General Systemic Johalation D						
DNEL Inhalation DNEL Long term Dermal DNEL NELCong term Dermal Inhalation DNEL0.43 mg/m³ General bw/day General opulation WorkersSystemic systemic population WorkersDNEL DNELShort term Oral DNEL0.75 mg/m bw/day DNELGeneral opulation General population General populationSystemic population General populationDNEL DNELShort term Dermal Inhalation DNELShort term Dermal Inhalation DNEL1.5 mg/kg bw/dayGeneral opulationSystemic populationDNEL DNEL DNELShort term Dermal Inhalation DNEL1.5 mg/kg bw/dayGeneral opulationSystemic populationDNEL DNEL DNEL DNEL DNEL DNEL DNEL Long term Inhalation DNEL Long term Inhalation36 mg/kg bw/day BNEL DNEL DNEL Long term Oral Inhalation DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term DNEL Long term Inhalation DNEL Long term DNEL Long term DNEL DNEL Long term DNEL Long term DNEL DNEL Long term DNEL DNEL Long term DNEL Long term DNEL Long term DNEL DNEL DNEL DNEL Long term DNEL DNEL DNEL DNEL Long term DNEL DNE		DNEL	Long term Dermal			Systemic
Inhalation Long term DermalDown and the second sec						
DNELLong term Dermal bwiday0.5 mg/kg bwidayWorkersSystemic systemicDNELShort term Oral Inhalation0.75 mg/ bwidayGeneral populationSystemic populationDNELShort term Inhalation1.5 mg/kg bwidayWorkersSystemic populationDNELShort term Inhalation1.5 mg/kg bwidayWorkersSystemic populationDNELLong term Inhalation1.76 mg/ms bwidayWorkersSystemic populationDNELLong term Inhalation1.76 mg/ms bwidayWorkersSystemicDNELLong term Oral36 mg/kg bwidayGeneral population (Consumers)Systemic populationDNELLong term Oral36 mg/kg bwidayGeneral population (Consumers)Systemic populationDNELLong term Oral36 mg/kg bwidayGeneral population (Consumers)Systemic populationJ(2-methoxymethylethoxy)propanolDNELLong term Oral Inhalation36 mg/kg bwidaySystemic populationDNELLong term Oral36 mg/kg bwidaySystemic populationSystemic populationJ(2+)-Isothiazolone, 2-methyl-DNELLong term Inhalation0.021 mg/ m³WorkersSystemic Local m³J(2+)-Isothiazolone, 2-methyl-DNELLong term Inhalation0.021 mg/ m³WorkersLocal population (Consumers)JNELLong term Inhalation0.021 mg/ m³General population (Consumers)Systemi		DNEL		0.43 mg/m ³	General	Systemic
(2-methoxymethylethoxy)propanol DNEL Short term Oral bw/day General Systemic (2-methoxymethylethoxy)propanol DNEL Short term 1.29 mg/m ² General Systemic (2-methoxymethylethoxy)propanol DNEL Short term 1.5 mg/kg Workers Systemic (2-methoxymethylethoxy)propanol DNEL Long term 1.76 mg/m ² Workers Systemic (2-methoxymethylethoxy)propanol DNEL Long term 5.28 mg/m ² Workers Systemic (2-methoxymethylethoxy)propanol DNEL Long term 36 mg/kg General Systemic DNEL Long term 36 mg/kg Bw/day General Systemic DNEL Long term 37.2 mg/m ² General Systemic DNEL Long term 36 mg/kg Bw/day General Systemic DNEL Long term 37.2 mg/m ² General Systemic DNEL Long term 37.2 mg/m ² General Systemic JONEL Long term 38 mg/m ² Workers Systemic DNEL Long term 0.021 mg/m ² General Systemic JONEL Long term 0.021 mg/m ² Workers Systemic <			Inhalation		population	
Jone LShort term Oral Short term Dermal InhalationSoft term Dermal 0.75 mg/ kg bw/day 0.75 mg/ kg bw/day 0.75 mg/ kg bw/day 0.75 mg/ population WorkersSystemic population population WorkersSystemic population population WorkersSystemic population [Consumers] general <td></td> <td>DNEL</td> <td>Long term Dermal</td> <td>0.5 mg/kg</td> <td>Workers</td> <td>Systemic</td>		DNEL	Long term Dermal	0.5 mg/kg	Workers	Systemic
kg bw/day population (2-methoxymethylethoxy)propanolDNEL Short term Dermal 			-	bw/day		
Image: space s		DNEL	Short term Oral	0.75 mg/	General	Systemic
DNELShort term Dermal kg bw/dayO.75 mg/ kg bw/dayGeneral populationSystemic populationDNELShort term Inhalation1.29 mg/m3General populationSystemicDNELShort term Dermal Inhalation1.5 mg/kg bw/dayWorkersSystemicDNELLong term Inhalation1.76 mg/m3WorkersSystemicDNELLong term Inhalation1.76 mg/m3WorkersSystemicDNELLong term Oral Inhalation36 mg/kg bw/dayGeneral Doulation [Consumers]SystemicDNELLong term Oral Inhalation36 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Oral Inhalation36 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal Inhalation121 mg/kg bw/dayGeneral generalSystemic populationJ(2H)-Isothiazolone, 2-methyl-DNEL DNELLong term Dermal Inhalation121 mg/kg m3General generalSystemic populationJ(2H)-Isothiazolone, 2-methyl-DNEL DNELLong term Inhalation0.021 mg/ m3WorkersLocal populationJ(2H)-Isothiazolone, 2-methyl-DNEL DNELShort term Inhalation0.043 mg/ m3General generalSystemicDNEL InhalationDNEL InhalationDO43 mg/ m3General General generalLocal population [Consumers]Local population [Consumers]DNEL InhalationDNEL Inhalation				•	population	
Image: constraint of the system indication inhalation inhalat		DNEL	Short term Dermal			Systemic
DNELShort term inhalation1.29 mg/m³ populationGeneral populationSystemic(2-methoxymethylethoxy)propanolDNELShort term inhalation1.76 mg/m³WorkersSystemic(2-methoxymethylethoxy)propanolDNELLong term inhalation5.28 mg/m³WorkersSystemicDNELShort term inhalation5.28 mg/m³WorkersSystemicDNELLong term Oral36 mg/kg bw/dayGeneral population [Consumers]SystemicDNELLong term Oral36 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Oral36 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal inhalation121 mg/kg bw/dayGeneral populationSystemic populationJ2(H)-Isothiazolone, 2-methyl-DNEL DNELLong term inhalation0.021 mg/ m³WorkersSystemic populationJ2(H)-Isothiazolone, 2-methyl-DNEL DNELLong term inhalation0.021 mg/ m³General populationLocal populationJ2(H)-Isothiazolone, 2-methyl-DNEL DNELLong term inhalation0.021 mg/ m³General populationLocal populationJ2(H)-Isothiazolone, 2-methyl-DNEL DNELShort term inhalation0.021 mg/ m³General population [Consumers]Local population [Consumers]J2(H)-Isothiazolone, 2-methyl-DNEL DNELShort term inhalation0.021 mg/ m³General population [Consu					population	
InhalationpopulationWorkersSystemicDNELShort term Dermal1.5 mg/kg bw/dayWorkersSystemic(2-methoxymethylethoxy)propanolDNELLong term Inhalation1.76 mg/m³WorkersSystemicDNELShort term Inhalation5.28 mg/m³WorkersSystemicDNELShort term Inhalation36 mg/kg bw/dayGeneral population [Consumers]SystemicDNELLong term Oral36 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Oral Inhalation36 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Oral Inhalation36 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal Inhalation121 mg/kg bw/dayGeneral populationSystemic population3(2H)-Isothiazolone, 2-methyl-DNELLong term Inhalation0.021 mg/ m³WorkersLocal population3(2H)-Isothiazolone, 2-methyl-DNELShort term Inhalation0.021 mg/ m³WorkersLocal populationDNELShort term Inhalation0.043 mg/ m³General populationLocal populationDNELShort term Oral0.027 mg/ rgGeneral populationLocal populationDNELShort term Oral0.027 mg/ rgGeneral populationLocal populationDNELShort term Oral0.027 mg/ rgGeneral populationLocal population		DNEL	Short term			Svstemic
DNELShort term Dermal bw/day1.5 mg/kg bw/dayWorkersSystemic(2-methoxymethylethoxy)propanolDNELLong term inhalation DNEL1.76 mg/m³WorkersSystemic(2-methoxymethylethoxy)propanolDNELLong term Oral DNEL36 mg/kg bw/dayGeneral population gonulation gonulationSystemicDNELLong term Oral36 mg/kg bw/dayGeneral population gonulationSystemicDNELLong term Oral36 mg/kg bw/dayGeneral populationSystemicDNELLong term Oral Inhalation36 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal Inhalation121 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal Inhalation121 mg/kg bw/dayWorkersSystemic3(2H)-Isothiazolone, 2-methyl-DNEL DNELLong term DNEL0.021 mg/ m³WorkersLocal inhalation3(2H)-Isothiazolone, 2-methyl-DNEL DNELLong term DNEL0.021 mg/ m³WorkersLocal inhalationDNELShort term DNEL0.021 mg/ m³WorkersLocal inhalationConsumers] inhalationConsumers] inhalationConsumers] inhalationLocal inhalationDNELShort term DNEL0.027 mg/ m³General generalLocal populationLocal ipopulationLocal ipopulationDNELLong term Oral0.027 mg/ m³General generalLocal ipopulationL						-,
bw/daybw/day(2-methoxymethylethoxy)propanolDNELLong term Inhalation1.76 mg/m3WorkersSystemicDNELDNELShort term Inhalation5.28 mg/m3WorkersSystemicDNELLong term Oral36 mg/kg bw/dayGeneral population [Consumers]SystemicDNELLong term Oral36 mg/kg bw/dayGeneral populationSystemicDNELLong term Oral36 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal Inhalation121 mg/kg bw/dayGeneral populationSystemic populationJONELLong term Dermal Inhalation121 mg/kg bw/dayGeneral populationSystemic population3(2H)-Isothiazolone, 2-methyl-DNELLong term Inhalation0.021 mg/ m³WorkersSystemic Local m³3(2H)-Isothiazolone, 2-methyl-DNELLong term Inhalation0.021 mg/ m³WorkersLocal populationJNELLong term Inhalation0.021 mg/ m³WorkersLocal populationDNELShort term Inhalation0.021 mg/ m³General populationLocal populationDNELLong term Oral0.027 mg/ m³General populationLocal populationDNELLong term Oral0.027 mg/ kg bw/dayGeneral populationLocal populationDNELLong term Oral0.027 mg/ kg bw/dayGeneral populationSystemicDNELLong term Oral </td <td></td> <td>DNEL</td> <td></td> <td>1.5 ma/ka</td> <td></td> <td>Systemic</td>		DNEL		1.5 ma/ka		Systemic
DNEL (2-methoxymethylethoxy)propanolDNEL InhalationLong term Inhalation1.76 mg/m³ WorkersWorkersSystemic(2-methoxymethylethoxy)propanolDNEL DNELShort term Inhalation5.28 mg/m³ bw/dayGeneral opulation [Consumers]]Systemic population [Consumers]]Systemic population [Consumers]]DNEL DNELLong term Oral Inhalation36 mg/kg bw/dayGeneral opulation general populationSystemic populationDNEL DNEL Long term Dermal27.2 mg/m³ bw/dayGeneral opulationSystemic populationDNEL DNEL Long term Dermal121 mg/kg bw/day bw/dayGeneral populationSystemic population3(2H)-Isothiazolone, 2-methyl-DNEL DNEL Long term Inhalation DNEL DNEL Long term Inhalation DNEL DNEL Long term DNEL DNEL Long term DNEL Long term DNEL Long term DNEL Long term DNEL DNEL Long term DNEL Long term DNEL Long term DNEL 						
Inhalation Short term Inhalation5.28 mg/m³WorkersSystemic(2-methoxymethylethoxy)propanolDNEL DNELLong term Oral Long term Oral36 mg/kg bw/dayGeneral population [Consumers] General population DNELSystemic population DNELDNEL InhalationLong term Oral Inhalation36 mg/kg bw/dayGeneral population general populationSystemic populationDNEL InhalationLong term Oral Inhalation37.2 mg/m³ Beneral populationSystemic populationDNEL InhalationLong term Dermal Inhalation121 mg/kg bw/day WorkersSystemic population3(2H)-Isothiazolone, 2-methyl-DNEL DNEL Long term Inhalation0.021 mg/ m³ MorkersWorkers Local m³Systemic population3(2H)-Isothiazolone, 2-methyl-DNEL DNEL Long term Inhalation0.021 mg/ m³ m³Workers Local population [Consumers] General population [Consumers]Local population m³3(2H)-Isothiazolone, 2-methyl-DNEL DNEL Long term Inhalation0.021 mg/ m³ m³Workers Local population [Consumers] General population [Consumers] [Consumers] [Consumers] [Consumers]Local population [Consumers] [Consumers] [Consumers] [Consumers] [Consumers] [Consumers]Local population [Consumers] [Consumers] [Consumers] [Consumers] [Consumers]Local population [Consumers] [Consumers] [Consumers] [Consumers]DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL		DNEI	l ong term		Workers	Systemic
DNELShort term Inhalation5.28 mg/m³WorkersSystemic(2-methoxymethylethoxy)propanolDNELLong term Oral36 mg/kg bw/dayGeneral population [Consumers]SystemicDNELLong term Oral36 mg/kg bw/dayGeneral populationSystemicDNELLong term Oral36 mg/kg bw/dayGeneral populationSystemicDNELLong term Oral36 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal121 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal283 mg/kg bw/dayWorkersSystemicDNELLong term Dermal283 mg/kg bw/dayWorkersSystemicDNELLong term Inhalation308 mg/m³WorkersSystemicJ(2H)-Isothiazolone, 2-methyl-DNELLong term Inhalation0.021 mg/ m³WorkersLocalDNELLong term Inhalation0.021 mg/ m³General population [Consumers]LocalDNELShort term Inhalation0.043 mg/ m³General population [Consumers]LocalDNELShort term Inhalation0.043 mg/ m³General population [Consumers]SystemicDNELLong term Oral0.027 mg/ m³General generalSystemicDNELLong term Oral0.027 mg/ m³General generalLocal population [Consumers]DNELLong term Oral0.027 mg/ generalGeneral generalSyste		DILL	-	1.7 0 mg/m		Cyclonnic
Inhalation Long term Oral36 mg/kg bw/dayGeneral population [Consumers]Systemic population [Consumers](2-methoxymethylethoxy)propanolDNEL DNELLong term Oral DNEL36 mg/kg bw/dayGeneral population [Consumers]Systemic population general populationDNEL InhalationLong term Oral Inhalation36 mg/kg bw/dayGeneral populationSystemic populationDNEL InhalationLong term Dermal Inhalation121 mg/kg bw/dayGeneral populationSystemic population3(2H)-Isothiazolone, 2-methyl-DNEL DNELLong term Dermal Inhalation121 mg/kg DNELWorkersSystemic3(2H)-Isothiazolone, 2-methyl-DNEL DNELLong term Long term0.021 mg/ m³WorkersLocal LocalDNEL InhalationDNEL InhalationLong term m³0.021 mg/ m³WorkersLocal LocalDNEL InhalationDNEL InhalationShort term m³0.021 mg/ general population [Consumers]Local population [Consumers]Local population [Consumers]DNEL DNEL InhalationShort term m³0.043 mg/ general population [Consumers]Local population [Consumers]DNEL DNEL InhalationShort term Oral0.027 mg/ general general population [Consumers]SystemicDNEL InhalationShort term Oral0.027 mg/ general general population [Consumers]Systemic		DNEI		5.28 mg/m^3	Workers	Systemic
(2-methoxymethylethoxy)propanolDNELLong term Oral36 mg/kg bw/dayGeneral population [Consumers]]SystemicDNELLong term Oral36 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Oral37.2 mg/m³General populationSystemic populationDNELLong term Dermal Inhalation121 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal Inhalation121 mg/kg bw/dayWorkersSystemic3(2H)-lsothiazolone, 2-methyl-DNELLong term Inhalation0.021 mg/ m³WorkersLocalDNELLong term Inhalation0.021 mg/ m³WorkersLocalDNELShort term Inhalation0.021 mg/ m³General populationLocalDNELShort term Inhalation0.043 mg/ m³General populationLocal populationDNELShort term Inhalation0.021 mg/ m³General populationLocal populationDNELShort term Inhalation0.027 mg/ generalGeneral populationLocal populationDNELLong term Oral0.027 mg/ generalGeneral populationSystemicDNELLong term Oral0.053 mg/General generalSystemic		DINEL		5.20 mg/m	WOINCIS	Oysterine
Jack LandowJack Landowbw/daypopulation [Consumers] GeneralSystemicDNELLong term Oral36 mg/kg bw/dayGeneral populationSystemicDNELLong term Inhalation37.2 mg/m³General populationSystemicDNELLong term Dermal121 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal283 mg/kg bw/dayWorkersSystemicDNELLong term Dermal308 mg/m³WorkersSystemicDNELLong term Inhalation0.021 mg/ m³WorkersLocalDNELShort term Inhalation0.043 mg/ m³WorkersLocalDNELLong term Inhalation0.021 mg/ m³General populationLocalDNELLong term Inhalation0.021 mg/ m³General populationLocalDNELLong term Inhalation0.021 mg/ m³General populationLocalDNELLong term Inhalation0.021 mg/ m³General populationLocalDNELLong term Oral0.027 mg/ kg bw/daySystemicSystemicDNELLong term Oral0.027 mg/ kg bw/daySystemicSystemicDNELShort term Oral0.053 mg/General populationSystemic	(2-methoxymethylethoxy)propanol			36 ma/ka	General	Svetemic
JNELLong term Oral36 mg/kg bw/day[Consumers] General populationSystemicDNELLong term inhalation37.2 mg/m³General populationSystemicDNELLong term Dermal121 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal121 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal283 mg/kg bw/dayWorkersSystemicJ(2H)-Isothiazolone, 2-methyl-DNELLong term Inhalation0.021 mg/ m³WorkersLocalDNELShort term inhalation0.021 mg/ m³WorkersLocalDNELShort term inhalation0.021 mg/ m³General populationLocalDNELShort term inhalation0.021 mg/ m³General populationLocalDNELShort term inhalation0.021 mg/ m³General populationLocalDNELShort term inhalation0.021 mg/ m³General populationLocalDNELLong term Oral0.027 mg/ kg bw/daySystemicSystemicDNELLong term Oral0.027 mg/ kg bw/daySystemicSystemicDNELShort term Oral0.053 mg/General populationSystemic		DINEL	Long term Ora			Oysternic
DNELLong term Oral36 mg/kg bw/dayGeneral populationSystemicDNELLong term37.2 mg/m³General populationSystemicDNELLong term Dermal121 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal121 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal283 mg/kg bw/dayWorkersSystemicDNELLong term Inhalation308 mg/m³WorkersSystemicDNELLong term Inhalation0.021 mg/ m³WorkersLocalDNELLong term Inhalation0.043 mg/ m³WorkersLocalDNELLong term Inhalation0.043 mg/ m³General populationLocalDNELLong term Inhalation0.043 mg/ m³General populationLocalDNELShort term Inhalation0.043 mg/ m³General populationLocalDNELLong term Oral0.027 mg/ kg bw/dayGeneral populationSystemicDNELLong term Oral0.053 mg/General populationSystemic				DW/Uay		
Jack SectorJack SectorJack SectorJack SectorJack SectorDNELLong term37.2 mg/m³populationSystemicJack SectorDNELLong term Dermal121 mg/kgGeneralSystemicJack SectorDNELLong term Dermal121 mg/kgGeneralSystemicJack SectorDNELLong term Dermal283 mg/kgWorkersSystemicJack SectorDNELLong term308 mg/m³WorkersSystemicJack SectorDNELLong term0.021 mg/WorkersLocalJack SectorDNELShort term0.021 mg/MorkersLocalJack SectorDNELShort term0.021 mg/GeneralLocalJack SectorDNELShort term0.043 mg/GeneralLocalJack SectorDNELShort term0.027 mg/GeneralLocalJack SectorDNELLong term Oral0.027 mg/GeneralSystemicJack SectorDNELShort term Oral0.027 mg/GeneralSystemicJack SectorDNELShort term Oral0.053 mg/GeneralSystemicJack SectorJack SectorJack SectorSystemicSystemicJack SectorJack Sector<			Long torm Oral	26 ma/ka		Svetomie
DNELLong term Inhalation37.2 mg/m³General populationSystemicDNELLong term Dermal121 mg/kgGeneral populationSystemicDNELLong term Dermal283 mg/kgWorkersSystemicDNELLong term308 mg/m³WorkersSystemicJ(2H)-Isothiazolone, 2-methyl-DNELLong term Inhalation0.021 mg/ m³WorkersLocalDNELShort term0.043 mg/ InhalationWorkersLocalDNELShort term0.021 mg/ InhalationGeneral m³LocalDNELShort term0.043 mg/ InhalationGeneral populationLocalDNELShort term0.021 mg/ InhalationGeneral population [Consumers]LocalDNELShort term0.027 mg/ kg bw/dayGeneral population [Consumers]Local population [Consumers]DNELShort term Oral0.027 mg/ kg bw/dayGeneral population [Consumers]Systemic		DNEL	Long term Oral			Systemic
Jack StrengthInhalation Long term Dermalpopulation General populationSystemicJack StrengthDNELLong term Dermal121 mg/kg bw/dayGeneral populationSystemicJack StrengthDNELLong term Dermal283 mg/kg bw/dayWorkersSystemicJack StrengthDNELLong term Inhalation308 mg/m³WorkersSystemicJack StrengthDNELLong term Inhalation0.021 mg/ m³WorkersLocalJack StrengthDNELShort term Inhalation0.043 mg/ m³WorkersLocalJack StrengthDNELShort term Inhalation0.043 mg/ m³General population [Consumers]]LocalJack StrengthDNELShort term Inhalation0.043 mg/ m³General population [Consumers]]LocalJack StrengthDNELLong term Oral0.027 mg/ kg bw/dayGeneral population [Consumers]]SystemicJack StrengthDNELShort term Oral0.053 mg/General general populationSystemic			Long torm			Svetomic
DNELLong term Dermal121 mg/kg bw/dayGeneral populationSystemic3(2H)-Isothiazolone, 2-methyl-DNELLong term Dermal283 mg/kg bw/dayWorkersSystemic3(2H)-Isothiazolone, 2-methyl-DNELLong term Inhalation0.021 mg/ m³WorkersLocalDNELLong term Inhalation0.021 mg/ m³WorkersLocalDNELShort term Inhalation0.021 mg/ m³WorkersLocalDNELShort term Inhalation0.021 mg/ m³General population [Consumers]LocalDNELShort term Inhalation0.021 mg/ m³General population [Consumers]LocalDNELShort term Inhalation0.043 mg/ m³General population [Consumers]LocalDNELShort term Oral0.027 mg/ kg bw/dayGeneral population [Consumers]SystemicDNELLong term Oral0.027 mg/ kg bw/dayGeneral population [Consumers]Systemic		DINEL		Sr.Z mg/m°		Systemic
3(2H)-Isothiazolone, 2-methyl-DNEL DNELLong term Dermal Long term Inhalationbw/day 283 mg/kg bw/daypopulation WorkersSystemic3(2H)-Isothiazolone, 2-methyl-DNEL DNELLong term Inhalation0.021 mg/ m³WorkersLocal LocalDNEL Inhalation DNELDNEL InhalationDot term 0.043 mg/0.021 mg/ WorkersWorkersLocal LocalDNEL Inhalation DNELShort term Inhalation0.043 mg/ m³WorkersLocal population [Consumers]DNEL DNEL DNELShort term Inhalation0.043 mg/ m³General population [Consumers]Local population [Consumers]DNEL DNEL DNELLong term Oral0.027 mg/ kg bw/dayGeneral population [Consumers]SystemicDNEL DNELShort term Oral0.027 mg/ kg bw/dayGeneral population [Consumers]Systemic				101		Sustantia
JacksonDNELLong term Dermal283 mg/kg bw/dayWorkersSystemic3(2H)-Isothiazolone, 2-methyl-DNELLong term Inhalation308 mg/m³WorkersSystemic3(2H)-Isothiazolone, 2-methyl-DNELLong term Inhalation0.021 mg/ m³WorkersLocalDNELShort term Inhalation0.043 mg/ m³WorkersLocalDNELShort term Inhalation0.021 mg/ m³General population [Consumers]LocalDNELLong term Inhalation0.021 mg/ m³General population [Consumers]LocalDNELShort term Inhalation0.043 mg/ m³General population [Consumers]LocalDNELShort term Inhalation0.027 mg/ kg bw/dayGeneral population [Consumers]SystemicDNELLong term Oral0.027 mg/ kg bw/dayGeneral population [Consumers]Systemic		DNEL	Long term Dermal			Systemic
3(2H)-Isothiazolone, 2-methyl-DNELLong term Inhalationbw/day 308 mg/m³WorkersSystemic3(2H)-Isothiazolone, 2-methyl-DNELLong term Inhalation0.021 mg/ m³WorkersLocalDNELShort term0.043 mg/ InhalationWorkersLocalDNELShort term0.021 mg/ InhalationGeneral populationLocalDNELShort term0.021 mg/ InhalationGeneral populationLocalDNELShort term0.043 mg/ InhalationGeneral populationLocalDNELShort term0.043 mg/ InhalationGeneral populationLocalDNELShort term0.027 mg/ kg bw/dayGeneral populationLocalDNELLong term Oral0.027 mg/ kg bw/dayGeneral populationSystemicDNELShort term Oral0.053 mg/General SystemicSystemic			Langeterme D			Overtex-:-
3(2H)-Isothiazolone, 2-methyl-DNELLong term Inhalation308 mg/m³WorkersSystemic3(2H)-Isothiazolone, 2-methyl-DNELLong term Inhalation0.021 mg/ m³WorkersLocalDNELShort term Inhalation0.043 mg/ m³WorkersLocalDNELShort term Inhalation0.021 mg/ m³General population [Consumers]LocalDNELLong term Inhalation0.021 mg/ m³General population [Consumers]LocalDNELShort term Inhalation0.043 mg/ m³General population [Consumers]LocalDNELShort term Inhalation0.043 mg/ m³General population [Consumers]LocalDNELShort term Oral0.027 mg/ kg bw/dayGeneral population [Consumers]SystemicDNELShort term Oral0.053 mg/General GeneralSystemic		DNEL	Long term Dermal		vvorkers	Systemic
3(2H)-Isothiazolone, 2-methyl-InhalationInhalation0.021 mg/ m³WorkersLocalDNELDNELShort term0.043 mg/ InhalationWorkersLocalDNELShort term0.021 mg/ InhalationGeneral population [Consumers]]LocalDNELShort term0.021 mg/ InhalationGeneral population [Consumers]]LocalDNELShort term Inhalation0.043 mg/ m³General population [Consumers]]LocalDNELShort term Inhalation0.043 mg/ m³General population [Consumers]]LocalDNELShort term Oral0.027 mg/ kg bw/dayGeneral population [Consumers]]SystemicDNELShort term Oral0.053 mg/ GeneralSystemic						
3(2H)-Isothiazolone, 2-methyl-DNELLong term Inhalation0.021 mg/ m³WorkersLocalDNELShort term Inhalation0.043 mg/ m³WorkersLocalDNELShort term Inhalation0.021 mg/ m³General population [Consumers]LocalDNELShort term Inhalation0.021 mg/ m³General population [Consumers]LocalDNELShort term Inhalation0.043 mg/ m³General population [Consumers]LocalDNELShort term Inhalation0.027 mg/ kg bw/dayGeneral population [Consumers]SystemicDNELLong term Oral0.027 mg/ kg bw/dayGeneral population [Consumers]Systemic		DNEL		308 mg/m ³	vvorkers	Systemic
Inhalationm³WorkersLocalDNELShort term0.043 mg/ InhalationWorkersLocalDNELLong term0.021 mg/ InhalationGeneral population [Consumers]]LocalDNELShort term Inhalation0.043 mg/ m³General population [Consumers]]LocalDNELShort term Inhalation0.043 mg/ m³General population [Consumers]]LocalDNELShort term Inhalation0.027 mg/ kg bw/dayGeneral population [Consumers]]SystemicDNELLong term Oral0.027 mg/ kg bw/dayGeneral population [Consumers]]SystemicDNELShort term Oral0.053 mg/General GeneralSystemic						
DNELShort term Inhalation0.043 mg/ m³WorkersLocalDNELLong term Inhalation0.021 mg/ m³General population [Consumers]]LocalDNELShort term Inhalation0.043 mg/ m³General population [Consumers]]LocalDNELShort term Inhalation0.043 mg/ m³General population [Consumers]]LocalDNELShort term Oral0.027 mg/ kg bw/dayGeneral population [Consumers]]SystemicDNELShort term Oral0.053 mg/ GeneralGeneral population [Consumers]]Systemic	3(2H)-Isothiazolone, 2-methyl-	DNEL			Workers	Local
Inhalationm³GeneralLocalDNELLong term0.021 mg/generalLocalInhalationm³GeneralLocalDNELShort term0.043 mg/GeneralLocalInhalationm³GeneralLocalDNELShort term Oral0.027 mg/GeneralLocalDNELLong term Oral0.027 mg/GeneralSystemicDNELLong term Oral0.027 mg/GeneralSystemicDNELShort term Oral0.053 mg/GeneralSystemic						
DNELLong term Inhalation0.021 mg/ m³General population [Consumers]LocalDNELShort term Inhalation0.043 mg/ m³General population [Consumers]LocalDNELShort term Inhalation0.027 mg/ kg bw/dayGeneral population [Consumers]SystemicDNELLong term Oral0.027 mg/ kg bw/dayGeneral population [Consumers]SystemicDNELShort term Oral0.053 mg/General generalSystemic		DNEL			Workers	Local
Inhalationm³population [Consumers]DNELShort term Inhalation0.043 mg/ m³General population [Consumers]DNELLong term Oral0.027 mg/ kg bw/dayGeneral population [Consumers]DNELLong term Oral0.027 mg/ kg bw/daySystemic population [Consumers]DNELShort term Oral0.053 mg/General GeneralSystemic						
DNELShort term Inhalation0.043 mg/ m³[Consumers] General population [Consumers]LocalDNELLong term Oral0.027 mg/ kg bw/dayGeneral population [Consumers]Systemic population [Consumers]DNELShort term Oral0.053 mg/General GeneralSystemic Systemic		DNEL				Local
DNELShort term Inhalation0.043 mg/ m³General population [Consumers]LocalDNELLong term Oral0.027 mg/ kg bw/dayGeneral population [Consumers]Systemic SystemicDNELShort term Oral0.053 mg/General GeneralSystemic			Inhalation	m³		
Inhalationm³population [Consumers]DNELLong term Oral0.027 mg/ kg bw/dayGeneral population [Consumers]DNELShort term Oral0.053 mg/GeneralSystemicSystemicSystemic					[Consumers]	
Inhalationm³population [Consumers]DNELLong term Oral0.027 mg/ kg bw/dayGeneral population [Consumers]DNELShort term Oral0.053 mg/GeneralSystemicSystemicSystemic		DNEL	Short term	0.043 mg/	General	Local
DNELLong term Oral0.027 mg/ kg bw/day[Consumers] General population [Consumers]SystemicDNELShort term Oral0.053 mg/General GeneralSystemic			Inhalation		population	
DNELLong term Oral0.027 mg/ kg bw/dayGeneral population [Consumers]SystemicDNELShort term Oral0.053 mg/GeneralSystemic						
kg bw/daypopulation [Consumers]DNELShort term Oral0.053 mg/GeneralSystemic		DNEL	Long term Oral	0.027 ma/		Systemic
DNEL Short term Oral 0.053 mg/ [Consumers] General Systemic				•		
DNEL Short term Oral 0.053 mg/ General Systemic						
		DNFI	Short term Oral	0.053 ma/		Systemic
$\frac{1}{10/25/2023}$				5.000 mg/		
	hete of icous/Data of revision	5/2022	Data of providence income	. 0/7/000) 17-	-

6/17

SECTION 8: Exposure controls/personal protection

oronion of rubbane cont	1013/p	ersonal protection		
		kg bw/day	population [Consumers]	

Product/ingredient name	Compartment Detail	Value	Method Detail
2-butoxyethanol	Fresh water	8.8 mg/l	-
	Marine water	0.88 mg/l	-
	Sewage Treatment Plant	463 mg/l	-
	Fresh water sediment	34.6 mg/kg dwt	-
	Marine water sediment	3.46 mg/kg dwt	-
	Soil	2.33 mg/kg dwt	-
	Secondary Poisoning	20 mg/kg	-
2,4,7,9-tetramethyldec-5-yne-4,7-diol	Fresh water	0.04 mg/l	-
	Marine water	0.004 mg/l	-
	Sewage Treatment	7 mg/l	-
	Plant	Ū.	
	Fresh water sediment	0.32 mg/kg dwt	-
	Marine water sediment	0.032 mg/kg dwt	-
	Soil	0.028 mg/kg dwt	-
2-methoxymethylethoxy)propanol	Fresh water	19 mg/l	Assessment Factors
	Marine water	1.9 mg/l	Assessment Factors
	Sewage Treatment Plant	4168 mg/l	Assessment Factors
	Fresh water sediment	70.2 mg/kg dwt	Equilibrium Partitionin
	Marine water sediment	7.02 mg/kg dwt	Equilibrium Partitionin
	Soil	2.74 mg/kg dwt	Equilibrium Partitionin
(2H)-Isothiazolone, 2-methyl-	Fresh water	3.39 µg/l	Assessment Factors
	Marine water	3.39 µg/l	Assessment Factors
	Sewage Treatment Plant	0.23 mg/l	Assessment Factors
	Soil	0.047 mg/kg dwt	Assessment Factors

8.2 Exposure controls

Appropriate engineering controls	: Good general ventilation should be sufficient to control worker exposure to airborne contaminants.
Individual protection measure	<u>Jres</u>
Hygiene measures	: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.
Eye/face protection	: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields. Recommended: chemical splash goggles and/or face shield.
Skin protection	
Hand protection	 Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated > 8 hours (breakthrough time): Recommended EN 374 foil butyl rubber fluor rubber >= 0.7 mm 4 hour (breakthrough time): Conditionally suitable materials for protective gloves; EN 374: Nitrile rubber - NBR (>= 0.35 mm). Only suitable as splash protection. Only suitable for brief exposure. In the event of contamination, change protective gloves
Date of issue/Date of revision	: 10/25/2023 Date of previous issue : 2/7/2023 Version : 1 7/1

SECTION 8: Exposure controls/personal protection

		immediately.
Body protection	:	Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. Recommended: Cotton or cotton/synthetic overalls or coveralls are normally suitable.
Other skin protection	:	Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Respiratory protection	:	Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use. Recommended: EN 405:2001 + A1:2009 organic vapour (Type A) and particulate filter FFA2P3 R D
Environmental exposure controls	:	Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

9.1 Information on basic physical and chemical properties

<u>Appearance</u>		
Physical state	Liquid.	
Colour	Red. [Transparent]	
Odour	Characteristic.	
Odour threshold	Not available.	
Melting point/freezing point	Not applicable.	
Initial boiling point and boiling range	100°C (212°F)	
Flammability (solid, gas)	Not available.	
Upper/lower flammability or explosive limits	Lower: 1.1% Upper: 10.6%	
Flash point	Closed cup: >93.3°C (>	199.9°F)
Auto-ignition temperature	230°C (446°F)	
Decomposition temperature	Not applicable.	
рН	7.9 to 8.1 [Conc. (% w/w	/): 100%]
Viscosity	Kinematic (40°C): >20.5	mm²/s
Solubility(ies)		
Media	Result	

Media		Result
cold water hot water		Soluble Easily soluble
Solubility in water	: N	Not applicable.
Miscible with water	: Y	Yes.
Partition coefficient: n-octanol/ water	: N	Not applicable.
Vapour pressure	: 2	2.3 kPa (17.5 mm Hg)
Evaporation rate	: 8	39 (butyl acetate = 1)
Relative density	: 0	D.999
Density	: 0	0.999 g/cm ³
Vapour density	: 1	1 [Air = 1]
Explosive properties	: N	Not available.
Oxidising properties	: N	Not available.
Particle characteristics		

Date of issue/Date of revision

SECTION 9: Physical and chemical properties

Median particle size

: Not applicable.

9.2 Other information Heat of combustion

: 3.084 kJ/g

SECTION 10: Stability and reactivity

10.1 Reactivity	: No specific test data related to reactivity available for this product or its ingredients.
10.2 Chemical stability	: The product is stable.
10.3 Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur.
10.4 Conditions to avoid	: No specific data.
10.5 Incompatible materials	: No specific data.
10.6 Hazardous decomposition products	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

Product/ingredient name	Result Specie		Dose	Exposure	
2-butoxyethanol	LC50 Inhalation Gas.	Rat	450 ppm	4 hours	
-	LD50 Dermal	Rabbit	220 mg/kg	-	
	LD50 Dermal	Rat	>2000 mg/kg	-	
	LD50 Oral	Rat	250 mg/kg	-	
2,4,7,9-tetramethyldec- 5-yne-4,7-diol	LD50 Dermal	Rabbit	>2000 mg/kg	-	
y y y y y y y y y y	LD50 Oral	Rat	>1860 mg/kg	-	
3(2H)-lsothiazolone, 2-methyl-	LD50 Oral	Rat	2131 mg/kg	-	

Conclusion/Summary : Not available.

Acute toxicity estimates

Product/ingredient name	Oral (mg/ kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapours) (mg/l)	Inhalation (dusts and mists) (mg/l)
MM 9153 WaterBase 900+ Series Translucent Maroon	14081.3	N/A	N/A	35.2	N/A 🥄
2-butoxyethanol 3(2H)-Isothiazolone, 2-methyl-	1200 100	N/A 300	N/A N/A	3 0.5	N/A N/A

Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
2-butoxyethanol	Eyes - Moderate irritant	Rabbit	-	24 hours 100	-
				mg	
	Eyes - Severe irritant	Rabbit	-	100 mg	-
	Skin - Mild irritant	Rabbit	-	500 mg	-
2,4,7,9-tetramethyldec-5-yne-	Eyes - Severe irritant	Rabbit	-	0.1 MI	-
4,7-diol					
	Skin - Mild irritant	Rabbit	-	0.5 gm	-
(2-methoxymethylethoxy)	Eyes - Mild irritant	Human	-	8 mg	-
propanol				_	
	Eyes - Mild irritant	Rabbit	-	24 hours 500	-
Date of issue/Date of revision	: 10/25/2023 Date of previous is	sue : 2/7/	2023	Versio	n :1 9/17

SECTION 11: Toxicological information

	Skin - Mild irritant	Rabbit	-	mg 500 mg	-
Conclusion/Summary	: Not available.			•	
<u>Sensitisation</u>					
Conclusion/Summary	: Not available.				
<u>Mutagenicity</u>					
Conclusion/Summary	: Not available.				
Carcinogenicity					
Conclusion/Summary	: Not available.				
Reproductive toxicity					
Conclusion/Summary	: Not available.				
Teratogenicity					
Conclusion/Summary	: Not available.				
Specific target organ toxi	<u>city (single exposure)</u>				
Not available.					<
Specific target organ toxi	<u>city (repeated exposure)</u>				
Product/ir	ngredient name	Category	Ro	ute of	Target organs

		exposure		
2,9-dimethylanthra[2,1,9-def:6,5,10-d'e'f']diisoquinoline- 1,3,8,10(2H,9H)-tetrone	Category 2	inhalation	-	

Aspiration hazard

Not available.

Information on likely routes	: Not available.
------------------------------	------------------

of exposure	
Potential acute health effects	

Eye contact	: No known significant effects or critical hazards.
Inhalation	: No known significant effects or critical hazards.
Skin contact	: May cause an allergic skin reaction.
Ingestion	: No known significant effects or critical hazards.

Symptoms related to the	phy	vsical, chemical and toxicological characteristic	S
	_		_

Eye contact	: No specific data.
Inhalation	: No specific data.
Skin contact	: Adverse symptoms may include the following: irritation redness
Ingestion	: No specific data.

Delayed and immediate effect	cts as well as chronic effects from sho	<u>rt and long-term exposure</u>	
Short term exposure			
Potential immediate effects	: Not available.		
Potential delayed effects	: Not available.		
<u>Long term exposure</u>			
Potential immediate effects	: Not available.		
Potential delayed effects	: Not available.		
Potential chronic health eff	<u>ects</u>		
Not available.			
Conclusion/Summary	: Not available.		
Date of issue/Date of revision	: 10/25/2023 Date of previous issue	: 2/7/2023 Ve	rsion

SECTION 11: Toxicological information

General	: Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.
Carcinogenicity	: No known significant effects or critical hazards.
Mutagenicity	: No known significant effects or critical hazards.
Reproductive toxicity	: No known significant effects or critical hazards.

Other information

: Not available.

SECTION 12: Ecological information

12.1	Toxicity
14.1	IONICITY

Product/ingredient name	Result	Species	Exposure
2-butoxyethanol	Acute EC50 911 mg/l	Algae - Pseudokrichneriella subcapitata	72 hours
	Acute EC50 1550 mg/l	Daphnia - <i>Daphnia magna</i>	48 hours
	Acute LC50 800000 µg/l Marine water	Crustaceans - Common shrimp, sand shrimp - Crangon crangon	48 hours
	Acute LC50 1250 ppm Marine water	Fish - Inland silverside - <i>Menidia</i> beryllina	96 hours
	Chronic NOEC 100 mg/l	Daphnia - <i>Daphnia magna</i>	21 days
	Chronic NOEC >100 mg/l	Fish - Brachydanio rerio	21 days
2,4,7,9-tetramethyldec- 5-yne-4,7-diol	Acute EC50 82 mg/l	Algae - Selenastrum capricornutum	72 hours
-	Acute EC50 91 mg/l	Daphnia - <i>Daphnia magna</i>	48 hours
	Acute LC50 36 mg/l	Fish - Elrits Pimephales	96 hours
(2-methoxymethylethoxy) propanol	Acute EC50 >1000 mg/l	Daphnia	48 hours
	Acute LC50 >1000 mg/l	Fish	96 hours
3(2H)-Isothiazolone, 2-methyl-	Acute EC50 0.157 mg/l	Algae - pseudokirchneriella subcapitata	72 hours
-	Acute EC50 1.68 mg/l	Daphnia	48 hours
	Acute LC50 6 mg/l	Fish	96 hours
	Chronic NOEC 0.03 mg/l	Algae - pseudokirchneriella subcapitata	72 hours
	Chronic NOEC 0.55 mg/l	Daphnia	21 days
	Chronic NOEC 2.38 mg/l	Fish	28 days

12.2 Persistence and degradability

Product/ingredient name	Test	Result		Dose	Inoculum
2-butoxyethanol	-	90.4 % - Readily - 28	3 days	-	-
Conclusion/Summary	: Not available.			l .	
Product/ingredient name	Aquatic half-life		Photolysis	5	Biodegradability
2-butoxyethanol	-	-	-		Readily

12.3 Bioaccumulative potential

Product/ingredient name	LogP _{ow}	BCF	Potential
2-butoxyethanol (2-methoxymethylethoxy) propanol	0.81 0.004	-	Low 🔽 Low

12.4 Mobility in soil

Soil/water partition coefficient (Koc) Mobility

: Not available.

: Not available.

MM 9153 WaterBase 900+ Series Translucent Maroon

SECTION 12: Ecological information

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Other adverse effects : No known significant effects or critical hazards.

SECTION 13: Disposal considerations

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

13.1 Waste treatment meth	ods
Product	
Methods of disposal	: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Hazardous waste	: The classification of the product may meet the criteria for a hazardous waste.
Packaging	
Methods of disposal	The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.
Special precautions	: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

	-			
	ADR/RID	ADN	IMDG	IATA
14.1 UN number	Not regulated.	Not regulated.	Not regulated.	Not regulated.
14.2 UN proper shipping name	-	-	-	-
14.3 Transport hazard class(es)	-	-	-	-
14.4 Packing group	-	-	-	-
14.5 Environmental hazards	No.	No.	No.	No.

14.6 Special precautions for user

: **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Transport in bulk according to IMO instruments

: Not available.

Date of issue/Date of revision

SECTION 15: Regulatory information

1

5.1 Safety, health and enviro UK (GB)/REACH	nmental regulations/legislation specific for the substance or mixture
	ces subject to authorisation
Annex XIV	
None of the components ar	e listed.
Substances of very high c	oncern
None of the components ar	e listed.
Ozone depleting substance	<u>§</u>
Not listed.	
Prior Informed Consent (PIC Not listed.	<u>D</u>
Persistent Organic Pollutan Not listed.	<u>ts</u>
Annex XVII - Restrictions on the manufacture,	: Not applicable.
placing on the market and	
use of certain dangerous	
substances, mixtures and articles	
Seveso Directive	
This product is not controlled u	nder the Seveso Directive.
EU regulations	
Industrial emissions (integrated pollution	: Not listed
prevention and control) -	
Air	
Industrial emissions	: Not listed
(integrated pollution prevention and control) -	
Water	
International regulations	
Chemical Weapon Convention	n List Schedules I, II & III Chemicals
Not listed.	
Montreal Protocol	
Not listed.	
Stockholm Convention on Per Not listed.	rsistent Organic Pollutants
Rotterdam Convention on Pr Not listed.	or Informed Consent (PIC)
UNECE Aarhus Protocol on F Not listed.	<u>'OPs and Heavy Metals</u>
Inventory list	
Australia	: All components are listed or exempted.
Canada	: Not determined.
China	: Not determined.
Eurasian Economic Union	: Russian Federation inventory: Not determined.
Japan	: Japan inventory (CSCL): At least one component is not listed. Japan inventory (ISHL): Not determined.
New Zealand	: All components are listed or exempted.

: 2/7/2023

SECTION 15: Regulatory information

-
: Not determined.
: All components are listed, exempted, or notified.
: Not determined.
: Not determined.
: Not determined.
: All components are active or exempted.
: Not determined.
: This product contains substances for which Chemical Safety Assessments are still required.

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and acronyms	: ATE = Acute Toxicity Estimate
	GB CLP = UK CLP (EC No 1272/2008) on the Classification, Labelling and
	Packaging of Substances and Mixtures as amended by (EU Exit) Regulations 2019
	No. 720 and amendments
	DMEL = Derived Minimal Effect Level
	DNEL = Derived No Effect Level
	EUH statement = GB CLP-specific Hazard statement
	N/A = Not available
	PBT = Persistent, Bioaccumulative and Toxic
	PNEC = Predicted No Effect Concentration
	RRN = REACH Registration Number
	SGG = Segregation Group
	vPvB = Very Persistent and Very Bioaccumulative

Procedure used to derive the classification

Classification	Justification	
Skin Sens. 1, H317	Calculation method	

Full text of abbreviated H statements

H301	Toxic if swallowed.	
H302	Harmful if swallowed.	
H311	Toxic in contact with skin.	
H314	Causes severe skin burns and eye damage.	
H315	Causes skin irritation.	
H317	May cause an allergic skin reaction.	
H318	Causes serious eye damage.	
H319	Causes serious eye irritation.	
H330	Fatal if inhaled.	
H331	Toxic if inhaled.	
H373	May cause damage to organs through prolonged or repeated exposure.	
H400	Very toxic to aquatic life.	
H410	Very toxic to aquatic life with long lasting effects.	
H412	Harmful to aquatic life with long lasting effects.	
EUH071	Corrosive to the respiratory tract.	

Full text of classifications

Acute Tox. 2	ACUTE TOXICITY - Category 2	
Acute Tox. 3	ACUTE TOXICITY - Category 3	
Acute Tox. 4	ACUTE TOXICITY - Category 4	
Aquatic Acute 1	SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1	
Aquatic Chronic 1	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1	
Aquatic Chronic 3	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3	
Eye Dam. 1	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1	
Eye Irrit. 2	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2	
Skin Corr. 1B	SKIN CORROSION/IRRITATION - Category 1B	
Skin Irrit. 2	SKIN CORROSION/IRRITATION - Category 2	
Skin Sens. 1	SKIN SENSITISATION - Category 1	
Skin Sens. 1A	SKIN SENSITISATION - Category 1A	
Skin Sens. 1B	SKIN SENSITISATION - Category 1B	

SECTION 16: Other information

STOT RE 2	SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 2
Date of printing	: 10/31/2023
Date of issue/ Date of revision	: 10/25/2023
Date of previous issue	e : 2/7/2023
Version	: 1

Notice to reader

To the best of our knowledge, the information contained herein is accurate. However, neither the above-named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.

SUMI Safe Use of Mixtures Information for end-users



Title

: Professional spray painting, near-industrial setting

This document is intended to communicate the conditions of safe use for the product and should always be read in combination with the product's Safety Data Sheet and labels.

General description of the process covered

Indoor spray painting by professionals with efficient ventilation such as spray booth or local exhaust ventilation

Operational conditions

Place of use

: Indoor use

Risk management measures (RMM)

Contributing activity	Process category (ies)	Maximum duration	Ventilation	
			Туре	ach (air changes per hour)
Preparation of material for application	PROC05	More than 4 hours	Enhanced (mechanical) room ventilation	5 - 10
Loading of application equipment and handling of coated parts before curing	PROC08a	More than 4 hours	Enhanced (mechanical) room ventilation	5 - 10
Professional application of coatings and inks by spraying	PROC11	More than 4 hours	Local exhaust ventilation	Refer to relevant technical standards
Film formation - force drying, stoving and other technologies	PROC04	More than 4 hours	Enhanced (mechanical) room ventilation	Refer to relevant technical standards
Cleaning	PROC05	More than 4 hours	Enhanced (mechanical) room ventilation	5 - 10
Waste management	PROC08a	More than 4 hours	Enhanced (mechanical) room ventilation	5 - 10
Contributing activity	Process category (ies)	Respiratory	Eye	Hands
Preparation of material for application	PROC05	None	Use eye protection according to EN 166.	Wear suitable gloves tested to EN374.
Loading of application equipment and handling of coated parts before curing	PROC08a	None	Use eye protection according to EN 166.	Wear suitable gloves tested to EN374.
Professional application of coatings and inks by spraying	PROC11	Wear a respirator conforming to EN140 with an assigned protection factor of at least 10.	Use eye protection according to EN 166.	Wear suitable gloves tested to EN374.
Film formation - force drying, stoving and other technologies	PROC04	Wear a respirator conforming to EN140 with an assigned protection factor of at least 10.	None	None
Cleaning	PROC05	None	Use eye protection according to EN 166.	Wear suitable gloves tested to EN374.
Waste management	PROC08a	None	Use eye protection according to EN 166.	Wear suitable gloves tested to EN374.

See chapter 8 of this Safety Data Sheet for specifications.

MM 9153 WaterBase 900+ Series Translucent Maroon



Disclaimer

The information in this Safe Use of Mixture Information sheet is based on the data provided by the substance supplier for the substances in the product for which a chemical safety assessment has been carried out at the time of issue. It does not guarantee safe use of the product and does not replace any occupational risk assessment required by legislation. When developing workplace instructions for employees, SUMI sheets should always be considered in combination with the SDS and the label of the product.

No liability is accepted for any damage, no matter of what kind, which is direct or indirect consequence of acts and/or decisions (partly) based on the contents of this document.